



# SILO WELLNESS

Delivering Psychedelic Healing Today

Corporate Presentation

CSE: [SILO](#) | OTC: [SILFF](#) | FRA: [3K70](#)

June 2021

# Disclaimer

The information contained in this presentation has been prepared by Silo Wellness Inc. ("**Silo Wellness**", "**SILO**" or the "**Company**") and contains confidential information pertaining to the business and operations of the Company. The information contained in this presentation: (a) is provided as at the date hereof, is subject to change without notice, and is based on publicly available information, internally developed data as well as third-party information from other sources; (b) does not purport to contain all the information that may be necessary or desirable to fully and accurately evaluate an investment in the Company; (c) is not to be considered as a recommendation by the Company that any person make an investment in the Company; and (d) is for information purposes only and shall not constitute an offer to buy, sell, issue or subscribe for, or the solicitation of an offer to buy, sell or issue, or subscribe for any securities of the Company in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction. Where any opinion or belief is expressed in this presentation, it is based on certain assumptions and limitations and is an expression of present opinion or belief only. The third-party information has not been independently verified. While the Company may not have verified the third-party information, it believes that it obtained the information from reliable sources and has no reason to believe it is not accurate in all material respects. No warranties or representations can be made as to the origin, validity, accuracy, completeness, currency or reliability of the information. The Company disclaims and excludes all liability (to the extent permitted by law), for losses, claims, damages, demands, costs and expenses of whatever nature arising in any way out of or in connection with the information in this presentation, its accuracy, completeness or by reason of reliance by any person on any of it. This presentation should not be construed as legal, financial or tax advice to any individual, as each individual's circumstances are different. Readers should consult with their own professional advisors regarding their particular circumstances and the Company assumes no liability for any consequences to the investor of any investment in the Company's securities.

A prospective investor is not entitled to rely on parts of the information contained in this presentation to the exclusion of others. The Company has not authorized anyone to provide prospective investors with additional or different information. This presentation does not contain all of the information that would normally appear in a prospectus under applicable Canadian securities laws. Neither the delivery of this presentation, at any time, nor any sale made pursuant to or in connection with this presentation, will imply that the information contained in the presentation is correct as of anytime subsequent to the date set forth on the cover page of the presentation or the date at which such information is expressed to be stated, as applicable.

No securities commission or regulatory authority in the United States, nor has any Canadian provincial or territorial securities regulator passed upon or endorsed the merits of the offering of any securities of the Company, nor have they approved this presentation or confirmed the accuracy or adequacy of the information contained in this presentation. Any representation to the contrary is a criminal offense.

Prospective investors are required to inform themselves about, and to observe any restrictions relating to any offering of the securities of the Company.

Any information in this presentation demonstrating or implying the historical performance of the Company or any other entity addressed in this presentation is intended only to illustrate past performance of such entities and are not necessarily indicative of future performance of the Company or such entities. An investment in the Company is speculative and involves substantial risk and is only suitable for investors that understand the potential consequences and are able to bear the risk of losing their entire investment. Prospective investors should review and consider carefully the information disclosed, including the "Risk Factors" described below and consult with their own legal, tax and financial advisors with respect to all such risks before making an investment.

The Company is in the early stage of development and has a limited operational history, making it difficult to accurately predict business operations. The Company has limited resources and may run out of capital prior to becoming profitable. The Company may fail and investors may lose their entire investment.

There is currently no market through which the securities of the Company may be sold, and one may never develop, meaning that purchasers may not be able to resell any securities purchased from the Company. The securities of the Company have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or the securities laws of any state of the United States and may not be offered and sold in the United States or to, or for the account or benefit of, U.S. Persons (as such term is defined in Regulation S under the U.S. Securities Act) except pursuant to an exemption from the registration requirements of the U.S. Securities Act and applicable state securities laws.

IN MAKING AN INVESTMENT DECISION, INVESTORS MUST RELY ON THEIR OWN EXAMINATION OF THE COMPANY AND THE TERMS OF ANY POTENTIAL INVESTMENT, INCLUDING THE MERITS AND RISKS INVOLVED. THE COMPANY'S SECURITIES HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE U.S. SECURITIES AND EXCHANGE COMMISSION OR BY ANY STATE SECURITIES COMMISSION OR REGULATORY AUTHORITY, NOR HAVE ANY OF THE FOREGOING AUTHORITIES OR ANY CANADIAN PROVINCIAL OR TERRITORIAL SECURITIES REGULATOR PASSED UPON OR ENDORSED THE MERITS OF THE SECURITIES NOR HAVE THEY APPROVED THIS PRESENTATION OR CONFIRMED THE ACCURACY OR ADEQUACY OF THE INFORMATION CONTAINED IN THIS PRESENTATION. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.

An investment in the Company may have tax consequences to the investor. The Company assumes no responsibility for the tax consequences of any investment. Investors should confer with their own tax advisors regarding an investment in the Company.



# Forward-looking Information

Certain statements in this presentation constitute forward-looking statements and forward-looking information within the meaning of applicable Canadian and United States securities legislation (collectively herein referred to as “forward-looking statements”), which can often be identified by words such as “will”, “may”, “estimate”, “expect”, “plan”, “project”, “intend”, “anticipate”, “target”, “believe”, “continue”, “outlook”, “forecast” and similar expressions or the negatives thereof. Except for statements of historical fact, certain information contained herein constitutes forward-looking statements which include but are not limited to statements related to activities, events or developments that the Company expects or anticipates will or may occur in the future, statements related to the Company’s business strategy objectives and goals, and management’s assessment of future plans and operations which are based on current internal expectations, estimates, projections, assumptions and beliefs, which may prove to be incorrect.

Such forward-looking statements are expectations only and are subject to known and unknown risks, uncertainties and other important factors that could cause the actual results, performance or achievements of the Company or industry results to differ materially from any future results, performance or achievements implied by such forward-looking statements, including, but not limited to: dependence on obtaining and maintaining regulatory approvals, acquiring and renewing state, local or other licenses; engaging in activities which currently are illegal under U.S. federal law, the laws of certain U.S. states and many foreign jurisdictions including Canada, and the uncertainty of existing protection from U.S. federal or other prosecution; regulatory or political change such as changes in applicable laws and regulations, including United States state-law legalization, if that occurs in the future, due to inconsistent public opinion, perception of the contemplated medical-use and adult-use psychedelics industries, bureaucratic delays or inefficiencies or any other reasons; any other factors or developments which may hinder market growth; the ability to complete proposed transactions and business plans as described, whether within proposed timeframes or at all; reliance on management; and the effect of capital market conditions and other factors on capital availability; competition, including from more established or better financed competitors; and the need to secure and maintain corporate alliances and partnerships, including with customers and suppliers. These factors should be considered carefully, and readers are cautioned not to place undue reliance on such forward-looking statements.

Readers are cautioned that the foregoing list and the risk factors under the heading “Risk Factors” are not exhaustive and there may be other risk factors that cause actions, events or results to differ from those anticipated, estimated or intended.

All of the forward-looking statements made in this presentation are qualified by these cautionary statements and other cautionary statements or other factors contained herein. Although management believes that the expectations conveyed by forward-looking statements herein are reasonable based on information available on the date such forward-looking statements are made, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such forward-looking statements. The Company undertakes no obligation to update any forward-looking statements, even if new information becomes available as a result of future events or if circumstances or management’s estimates or opinions should change or for any other reason, except as required by applicable securities laws. The forward-looking statements contained herein are presented for the purposes of assisting readers in understanding the Company’s plan, objectives and goals and may not be appropriate for other purposes.

Historical statements contained in this document regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. In this regard, certain financial information contained herein has been extracted from, or based upon, information available in the public domain and/or provided by the Company. In particular, historical results of the Company should not be taken as a representation that such trends will be replicated in the future. No statement in this document is intended to be nor may be construed as a profit forecast.

## CAUTIONARY NOTE REGARDING FUTURE-ORIENTED FINANCIAL INFORMATION

To the extent any forward-looking statement in this presentation constitutes “future-oriented financial information” or “financial outlooks” within the meaning of applicable Canadian securities laws, such information is being provided to demonstrate the anticipated market penetration and the reader is cautioned that this information may not be appropriate for any other purpose and the reader should not place undue reliance on such future-oriented financial information and financial outlooks. Future-oriented financial information and financial outlooks, as with forward-looking statements generally, are, without limitation, based on the assumptions and subject to the risks set out above under the heading “Forward Looking Information”. The Company’s actual financial position and results of operations may differ materially from management’s current expectations and, as a result, the Company’s revenue and expenses.

# Silo Wellness at a Glance

A revenue-generating global psychedelics and wellness company, delivering psychedelic healing today

1

## **A global psychedelics company not dependent on novel molecule clinical trial success**

Biopharmaceutical competition in the psychedelics space is fierce and costly

2

## **Unique combination of business lines that provide a diverse, future-proof company**

First-mover advantage to commercialize with broad, immediate revenue stream potential

3

## **Bridging modern science and indigenous traditions**

ESG-aware organization working with indigenous communities for our products and services

4

## **Generating revenue *now* with an expansive near-term revenue plan**

Services provided in two countries and global product distribution/licensing partnerships give us the broadest footprint in the industry

5

## **Growing an already robust portfolio of revenue lines**

Marley One mushroom brand, functional mushrooms, dose inhaler and psychedelic wellness retreats



**SILO WELLNESS**

CSE: SILO | OTC: SILFF | FRA: 3K70

# Market Opportunity

Psychedelic healing now mainstream during growing global mental illness pandemic

## Global Mental Health Conditions

**450M**

worldwide with  
mental health  
conditions

**322M**

suffer from  
depression

**354M**

adults with  
PTSD

**27M**

global opioid  
abusers

**\$631B**

cost of opioid  
crisis in the US  
(2015 to 2018)

**1 in 3**

globally suffers  
from anxiety

- Psychedelics-inspired medicines are well-positioned to address increasing patient base for mental and substance abuse disorders
- Canaccord estimates targeted indications to affect over **1.0 billion people globally**
- Prohibition Partners estimates potential savings on costs brought by psychedelic-assisted therapies in the U.S. to be over **US\$560 billion**


A 2017 US poll showed **59%** of consumers would consider using psychedelics as a treatment if diagnosed with mental health condition for which it had been proven effective

# Market Opportunity

Psilocybin demand expected to grow with anti-depressant as a key market

- The global anti-depressant drug market valued at \$13.8 billion in 2016, projected to grow to \$16.0 billion by 2023
- Psilocybin has additional therapeutic benefit easing existential anxiety in those with terminal diseases and alcoholism

## Global Anti-Depressant Drug Market



**Psilocybin demand will grow and compete with anti-depressant drugs for market share**

# Market for Functional Mushrooms and Global Wellness

Significant market opportunity and poised for disruption

*Millennials and Gen Xers are the biggest consumers of cosmeceuticals, supplements, and functional foods*

**30-55  
years old**

**College  
educated**

*Increasing popularity and demand for plant-based innovation in consumer products*

## Significant Market Opportunity

Global Wellness  
Market

**\$4.2T**

CAGR: 12.8%

Global  
Herbal Tea

**\$51B**

CAGR: 6.4%

Global  
Cosmeceuticals

**\$45B**

CAGR: 8.2%

Global Dietary  
Supplements

**\$133B**

CAGR: 8.8%

Global  
Functional Foods

**\$258B**

CAGR: 7.9%

Global  
CBD Market

**\$20B**

CAGR: 31%

Global  
Functional Mushrooms

**\$34B**

CAGR: 8.0%



# Inherent Biopharmaceutical Risks in Psychedelics

Clinical trials risky and expensive: It's an arm's race marathon at a sprinter's pace

## Biopharmaceutical competition in the psychedelics space is fierce and costly

- Dozens seeking more capital to conduct expensive and lengthy drug trials
- Developing novel molecules can take 15 years and cost in excess of \$1 billion
- Multiple companies using the same non-patentable natural molecules for specific indications in clinical trials is inherently risky for those not first to the finish line
- A significant number of clinical trials will fail to produce new, effective, and safe medicines

**~70%**  
of Phase II  
clinical trials fail

---


**~50%**  
of Phase III  
clinical trials fail

---

***“We will see an arms race in the psychedelic space as companies try to innovate and get their drugs to trials and to the market.”***

*of marijuanastocks.com*

*trader at true trading group.com*





# Silo Wellness Footprint



## SILO WELLNESS

SILO is a global psychedelics company bridging modern science, current laws and indigenous traditions to make psychedelics available today, wherever possible

Announced strategic partnership with Mushe Inc. to establish in Jamaica the first legal psychedelic and functional mushroom shop in the western hemisphere (June 2021)



SILO WELLNESS

CSE: SILO | OTC: SILFF | FRA: 3K70

# Diversified Investment: Silo Wellness

First-mover advantage to commercialize today; diverse, future-proof portfolio for tomorrow


Not dependent on novel molecules

A portfolio that expands as country and state-specific legislations evolve and markets open

Focused on access to psychedelics right now

## Silo Wellness Portfolio

- 1 Functional mushrooms with significant market opportunity
- 2 Mushrooms and truffle cultivation to service Silo Wellness operations today and industry needs tomorrow
- 3 Patent-pending metered dose psilocybin nasal spray that bypasses the gut for faster uptake-speed with controlled and predictable dosing
- 4 Psychedelic wellness retreats today in Jamaica (psilocybin and 5-MeO-DMT) and Oregon (ketamine), and additional retreats as we enter more markets and add new molecules



# Portfolio Breakout: Functional Mushrooms

Initial portfolio consisting of 16 Silo Wellness-branded SKUs and five Marley One SKUs

## Initial Functional Mushrooms Portfolio

- Entered the functional mushroom marketplace in 2018
- **Five Bob Marley-branded SKUs:** Brain (Lion's Mane), Lung (Cordyceps), Gut (Chaga), Sleep (Reishi) and Immune (Turkey Tail)
- **16 Silo Wellness-branded SKUs:** Lion's Mane, Cordyceps, Chaga, Reishi and Turkey Tail, and mushroom blend tinctures

SILO has created  
a product for  
every occasion



# Portfolio Breakout: Marley One

Creating the first-ever global mushroom brand with the Bob Marley Family

- Multi-year license agreement with the family of Bob Marley
- Exclusive worldwide rights to brand, market and sell a distinct product line of functional and psychedelic mushrooms
- Marley One will help accelerate customer understanding of functional mushroom category
- As psychedelic markets open, the Marley brand will carry over to other products and services within the Silo Wellness portfolio



**Marley** a beloved, globally relevant brand


**Forbes #5**

top-earning posthumous  
celebrity (2019)

**1 billion**

streams in the  
U.S. alone

Highly popular **Marley** branded  
products sold globally from cannabis  
to speakers to turntables





# Marley One

Instilled with Bob's philosophy

**Marley One – instilled with Bob's philosophy – can help address our world's needs in a warm and reassuring way, unlike many 'clinical' products or untrustworthy voices today**

- **Initial product portfolio of 5 leading functional mushroom tinctures:**
  - One Mind (Lion's Mane)
  - One Flow (Cordyceps)
  - One Harmony (Chaga)
  - One Rest (Reishi)
  - One Body (Turkey Tail)
- Supported by integrated marketing to drive retail traffic and eye-popping in-store signage
- Percentage of product sales to be contributed towards a charitable organization to be mutually agreed upon between the Marley family and SILO

*"When Bob and I were young we followed a strict, natural diet and we would include medicinal mushrooms. Mushrooms fit with our vision of a world transformed for good through natural products."*

**– Rita Marley**

**Marley One will launch with 5 SKUs initially**



# Portfolio Breakout: Jamaican Cultivation and Distribution

Establishing distribution network with the first legal psychedelic shop in the western hemisphere

## Cultivation of psilocybin mushrooms and truffles

- No permits or licenses are required to cultivate in Jamaica
- Used for current wellness retreat demands
- **Scalable to meet expanding market demand**
- Includes micro-dosing products, mushrooms and truffles



## Announced strategic partnership with Mushe Inc. to establish in Jamaica the first legal psychedelic and functional mushroom shop in the western hemisphere (June 2021)

- Silo Wellness and Mushe will build out and operate a “smart shop” retail establishment specializing in the sale of functional and psychoactive mushroom products
- Bob Marley branded products will be sold at the store upon launch
- Will serve as a direct-to-consumer educational channel for all Silo Wellness brands with both locals and tourists

# Portfolio Breakout: Psilocybin Metered-Dose Nasal Spray

Accurate measured dosing critical to a positive experience

**Problem:** Ingesting psilocybin mushrooms orally can cause discomfort to one's digestive system



**Solution:** In 2019, SILO established proof-of-concept of a psilocybin metered-dose nasal spray that makes psilocybin easier to administer and ingest



Bypasses the digestive system



Precise metered-dosing ensures higher degree of safety and consistency




Metered-dosing with faster uptake speed critical to prevent accidental high-dosage

## Initial IP Commercial Transaction with Jungle Med for Colombia and Brazil Markets

In April 2021, signed a multi-year patent licensing agreement to exclusively manufacture, promote, advertise, distribute and sell the patent-pending, metered-dosing psilocybin nasal spray in the countries of Colombia and Brazil.



JUNGLE MED



# Portfolio Breakout: Jamaica Psychedelic Wellness Retreat

Flagship first-of-its-kind Jamaica wellness retreat

- Conducting legal psilocybin- and 5-MeO-DMT-assisted retreats and mushroom and truffle cultivation workshops
- Formulation site for our proof-of-concept patent-pending psilocybin nasal spray
- SILO held its inaugural psychedelic wellness retreat on Feb 2021 at a rustic seaside resort property two hours from Montego Bay airport



## Key Partnerships

### Kaivalya Kollektiv (May 2021)

- Integrate a 5-MeO-DMT (the “Toad”) experience into two new Jamaican retreats
- First publicly traded company to offer a 5-MeO-DMT wellness retreat and first-of-its-kind to be held in Jamaica

### Ehave Inc. (March 2021)

- Provider of digital therapeutics for the psychedelic and mental health sectors
- Collaborate on a brain wave data-study in coordination with select volunteer participants of SILO’s Jamaican psilocybin-facilitated wellness retreats



EHAVE



# Portfolio Breakout: Oregon Psychedelic Wellness Retreat

Oregon wellness retreat

- Since January 2021, conducting legal, ketamine-assisted wellness retreats in Oregon under the care of an experienced Oregon ketamine-assisted therapy naturopathic physician
- In November 2020, Oregon passed Measure 109 authorizing the Oregon Health Authority to create regulations permitting licensed service providers to administer psilocybin-producing mushroom and fungi products in a therapeutic setting to individuals 21 years of age or older-



Silo Wellness intends to be 'turn-key ready' when Oregon opens by “importing” systems, procedures and expertise it has established in Jamaica

# Competitive Landscape

Undiscovered and undervalued compared to public peers

	SILO Wellness	Havn Life	Red Light Holland	Rise Wellness	Field Trip	Compass Pathways	MindMed
Instantly recognizable global brand	✓	X	X	X	X	X	X
Psychedelics wellness retreats	✓	X	X	✓	✓ <sup>(1)</sup>	X	X
Cultivation (psilocybin / truffle)	✓	✓	✓	X	X	X	X
Metered dose delivery vehicle for psilocybin	✓	X	✓	X	X	✓	✓
Functional mushrooms (retail)	✓	✓	X	X	X	X	X
Market Cap. (Jun 23, 2021)	C\$10M	C\$56M	C\$117M	Private	C\$408M	US\$1.3B	US\$1.2B

# Experienced Leadership Team

## Management

---

**Douglas K. Gordon**  
Chief Executive Officer

**Ryan Ptolemy, CPA, CGA, CFA**  
Chief Financial Officer

**Peter Holzworth**  
Vice President of Sales

**Kenny Choi**  
Legal Counsel and  
Corporate Secretary

## Board of Directors

---

**Mo Yang**  
Director

**Winfield Ding**  
Director

**Wayne Isaacs**  
Director

**Gregory Biniowsky**  
Director

**Mike Arnold**  
Director/President


## Advisory Board

---

**Dr. Parag Bhatt, PhD**  
Pharmacology

**Dr. Joseph Barsuglia, PhD**  
Psychedelic Psychology and  
Bioethics

**Michael Hartman**  
Psilocybin Nasal Spray Inventor;  
Inhaled Medicine



# Strategic Partners

Signed agreements and LOIs that give us a competitive advantage

EHAVE



**JAMAICA**  
RASTAFARI INDIGENOUS  
VILLAGE

MARLEY  
ONE

JUNGLE MED





# Capital Structure

## Current Capital Structure

Common Shares	62,879,704
Options	5,737,500
Fully-Diluted Shares	68,617,204
Share Price (C\$) (Jun 23, 2021)	C\$0.16
Market Cap, Basic (C\$M)	C\$10.1 million

## Ticker

CSE: SILO  
OTC: SILFF  
FRA: 3K70



**SILO WELLNESS**

Silo Wellness received gross proceeds of approximately C\$5 million in connection with the private placement that it completed concurrently with the reverse take-over transaction at C\$0.25 per unit of Silo Wellness.



# SILO WELLNESS

[silowellness.com](https://silowellness.com)

CSE: [SILO](#) | OTC: [SILFF](#) | FRA: [3K70](#)



**For more information**

[IR@silowellness.com](mailto:IR@silowellness.com)

+1 (604) 343-2724